TrialBioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy2021

Efficacy and Safety of Bevacizumab Biosimilar FKB238 Versus Originator Bevacizumab: Results from AVANA, a Phase III Trial in Patients with Non-Squamous Non-Small-Cell Lung Cancer (non-sq-NSCLC).

Konstantinos Syrigos et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.